These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35964542)

  • 1. Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome.
    Grigorova M; Mak E; Brown SSG; Beresford-Webb J; Hong YT; Fryer TD; Coles JP; Aigbirhio FI; Tudorascu D; Cohen A; Christian BT; Ances B; Handen BL; Laymon CM; Klunk WE; Clare ICH; Holland AJ; Zaman SH
    Neurobiol Aging; 2022 Nov; 119():36-45. PubMed ID: 35964542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
    Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A
    J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.
    Hartley SL; Handen BL; Devenny D; Mihaila I; Hardison R; Lao PJ; Klunk WE; Bulova P; Johnson SC; Christian BT
    Neurobiol Aging; 2017 Oct; 58():68-76. PubMed ID: 28715661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline.
    Cole JH; Annus T; Wilson LR; Remtulla R; Hong YT; Fryer TD; Acosta-Cabronero J; Cardenas-Blanco A; Smith R; Menon DK; Zaman SH; Nestor PJ; Holland AJ
    Neurobiol Aging; 2017 Aug; 56():41-49. PubMed ID: 28482213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
    Ismail R; Parbo P; Madsen LS; Hansen AK; Hansen KV; Schaldemose JL; Kjeldsen PL; Stokholm MG; Gottrup H; Eskildsen SF; Brooks DJ
    J Neuroinflammation; 2020 May; 17(1):151. PubMed ID: 32375809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
    Prokopiou PC; Engels-Domínguez N; Schultz AP; Sepulcre J; Koops EA; Papp KV; Marshall GA; Normandin MD; El Fakhri G; Rentz D; Sperling RA; Johnson KA; Jacobs HIL
    Neurology; 2023 Sep; 101(12):e1206-e1217. PubMed ID: 37491329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.
    Chen X; Cassady KE; Adams JN; Harrison TM; Baker SL; Jagust WJ
    J Neurosci; 2021 Jan; 41(2):366-375. PubMed ID: 33219003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects.
    Knopman DS; Lundt ES; Therneau TM; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Albertson SM; Schwarz CG; Petersen RC; Jack CR
    Brain; 2019 Apr; 142(4):1148-1160. PubMed ID: 30759182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia.
    Zhang RQ; Chen SD; Shen XN; Yang YX; Lu JY; Cui M; Zuo CT; Dong Q; Tan L; Yu JT;
    J Alzheimers Dis; 2020; 78(1):395-404. PubMed ID: 32986669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.